Sirakoss
Sirakoss is a Scotland-based medical device company that developed the proprietary silicate-substituted nanosynthetic bone graft technology now commercialized as OssDsign Catalyst. Acquired by OssDsign AB in November 2020, it operates as a wholly-owned subsidiary serving spine and orthopedic surgeons.
- Company typePublic
- Founded2011
- HeadquartersEdinburgh, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sirakoss does
Sirakoss is a Scotland-based medical device company founded in 2010 that developed a proprietary nanosynthetic, silicate-substituted calcium phosphate bone graft substitute. Its core technical differentiator is the direct substitution of silicate ions into the graft's calcium phosphate chemistry—rather than surface coating or carrier-based delivery—which provides sustained silicate signaling and activates a dual-pathway healing mechanism combining endochondral ossification with intramembranous bone formation. The product is now commercialized worldwide as OssDsign Catalyst, an off-the-shelf putty available in 1cc, 2.5cc, 5cc, and 10cc sizes, and is the first synthetic bone graft cleared by the FDA for use in spinal interbody fusions based on bone graft data alone.
In November 2020 Sirakoss was acquired by OssDsign AB (Nasdaq First North: OSSD; headquartered in Uppsala, Sweden) and now operates as a wholly-owned subsidiary. Following the acquisition, OssDsign discontinued its legacy patient-specific cranial implant business (OssDsign Cranial PSI) at the end of December 2023 to become a pure-play orthobiologics company focused on Catalyst. The technology is supported by the TOP FUSION first-in-human clinical study and the ongoing PROPEL Spine Registry—a multi-center, prospective study that has enrolled 365 patients across 15 sites in the U.S.—with reported 93% fusion rates within 12 months even in complex multi-level spinal surgeries.
The business model is direct B2B sale of a single Class-equivalent hardware product to hospitals, ambulatory surgical centers, and spine/orthopedic surgeons, primarily in the U.S. market (with presence in the UK, Germany, and Sweden). Commercial channels are concentrated on field sales supported by KOL engagement, clinical evidence publication, surgeon testimonials, and participation in major spine and orthopedic congresses (NASS, SMISS, AOFAS, etc.). Pricing is quote-based and not publicly disclosed; the parent has historically characterized the orthobiologics business as high gross margin and high scalability, and its major shareholders are predominantly Nordic institutional investors (Avania Pension 10.6%, Linc AB 10.0%, TAMT AB 8.1%, FSG Fund 7.2%).
Sirakoss firmographics
Firmographics- Name
- Sirakoss
- Legal name
- OssDsign AB
- Website
- https://sirakoss.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sirakoss is a Scotland-based medical device company that developed the proprietary silicate-substituted nanosynthetic bone graft technology now commercialized as OssDsign Catalyst. Acquired by OssDsign AB in November 2020, it operates as a wholly-owned subsidiary serving spine and orthopedic surgeons.
- Ownership category
- akta.pro rank
Sirakoss industry classification
Industry- Product category
- Orthobiologics / Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Sirakoss is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Sirakoss business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Medical Device Sales - Bone Graft Products: Revenue generated from the sale of OssDsign Catalyst nanosynthetic bone graft products to hospitals and surgical centers. Products are sold directly to healthcare providers for use in spinal fusion and orthopedic surgical procedures. The company characterizes its orthobiologics business as having high gross margins and high scalability.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
Sirakoss product offering
Product offeringCore offering
Sirakoss developed a next-generation nanosynthetic bone graft substitute designed to provide surgeons an easy-to-use and effective solution for treating skeletal defects with many applications including spinal fusion surgery. The technology is a silicate-substituted calcium phosphate synthetic bone graft with a dual-pathway healing mechanism. Following acquisition by OssDsign AB in November 2020, the technology has been commercialized as OssDsign Catalyst.
Product overview
OssDsign is a developer and global provider of next generation orthobiologics products. The company's product portfolio centers on OssDsign Catalyst, a nanosynthetic bone graft substitute designed for spinal fusion and bone healing applications. Following a September 2023 strategic shift, the company discontinued its patient-specific cranial implant business (OssDsign Cranial PSI) to become a pure-play orthobiologics company focused on the off-the-shelf Catalyst product. The company also conducts clinical studies including PROPEL Spine Registry and TOP FUSION to generate real-world evidence for Catalyst's performance.
Differentiator
Problem solved
Functional benefit
Brands
- OssDsign Catalyst: Nanosynthetic, silicate-substituted bone graft designed for spinal fusion and bone healing applications. The flagship orthobiologics product of the company.
- OssDsign Cranial PSI
Products and services
- Sirakoss Nanosynthetic Bone Graft Substitute (OssDsign Catalyst) A next-generation nanosynthetic, silicate-substituted calcium phosphate bone graft substitute designed for spinal fusion and bone healing applications, with a dual-pathway healing mechanism (endochondral ossification and intramembranous bone formation) and cell-mediated coupled remodeling. Targets spine surgeons, orthopedic surgeons, and hospitals for use in interbody fusion, cervical/thoracic/lumbar fusion, deformity correction, and extremity procedures.
Quantifiable outcome
- 93% fusion rates within 12 months in complex multi-level spinal surgeries
- +2 more outcomes
Companies that use Sirakoss
Customer profileNamed customers7 records
Segments2 records
Ideal customer profiles1 record
Sirakoss technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Sirakoss partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Sirakoss LtdcoreAcquired in November 2020, Sirakoss Ltd developed the OssDsign Catalyst nanosynthetic bone graft technology. This acquisition expanded OssDsign from cranial implants into orthobiologics. Tom Buckland, CTO, previously served as CEO of SIRAKOSS Ltd.
- Ernst & Young ABcoreRegistered audit firm elected at Annual General Meeting 2022. Oskar Wall is Chief Auditor.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Sirakoss competitors and assessment
Company assessmentDirect peers
- NuVasive (now part of Globus Medical): Spine surgery specialist with biologic bone graft products that compete head-to-head in spinal fusion with OssDsign Catalyst; the CTO of OssDsign was previously Managing Director of NuVasive UK.
- SeaSpine (now Orthofix Medical): Spine-focused pure-play with broad orthobiologics portfolio (including DBM, allograft, synthetic bone grafts) directly comparable to OssDsign Catalyst in spinal fusion applications.
- Cerapedics: Pure-play orthobiologics company commercialising i-FACTOR peptide-enhanced bone graft for cervical spine fusion, a direct competitor in FDA-cleared biologic bone graft substitutes.
- Xtant Medical: Pure-play orthobiologics company focused on bone graft substitutes and sports medicine, a small-cap comparable in scale and product breadth to OssDsign.
- Bone Biologics: Orthobiologics R&D-stage company developing recombinant protein bone graft (NELL-1/DBM) for spinal fusion; broadly comparable technology category and end market.
Broad incumbents
- Medtronic (Sofamor Danek): Dominant spine + biologics incumbent selling INFUSE rhBMP-2 bone graft and integrated hardware kits; the broader platform that OssDsign must dislodge in spinal fusion.
- Stryker: Large diversified orthopedics player offering bone graft substitutes (e.g., Vitoss, Bio4) as part of broader spine and extremities portfolios; competes with Catalyst in trauma and extremity indications.
- Baxter International: Holds the legacy ApaTech orthobiologics franchise where multiple OssDsign executives previously worked (CTO Tom Buckland co-founded ApaTech, VP Clinical Melanie Marshall was VP Clinical at ApaTech).
- Bioventus: Orthobiologics-focused public company providing bone graft substitutes and osteoarthritis pain treatments, comparable commercial-stage orthobiologics platform.
Emerging players
- Bonesupport: European-listed orthobiologics company commercialising antibiotic-loaded and synthetic bone graft technologies (CERAMENT); comparable pure-play/orthobiologics profile, peer for a public-listed synthetic bone graft company.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Sirakoss social profiles
Digital presenceSirakoss financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sirakoss leadership team
Management profileNumber of profiles
Profiles1 record
Sirakoss subsidiaries and ownership
Company hierarchySubsidiaries2 records
Sirakoss funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sirakoss M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sirakoss
What does Sirakoss do?
Sirakoss developed a next-generation nanosynthetic bone graft substitute designed to provide surgeons an easy-to-use and effective solution for treating skeletal defects with many applications including spinal fusion surgery. The technology is a silicate-substituted calcium phosphate synthetic bone graft with a dual-pathway healing mechanism. Following acquisition by OssDsign AB in November 2020, the technology has been commercialized as OssDsign Catalyst.
Is Sirakoss a public or private company?
Sirakoss is a public company. It is classified as corporate owned and is currently operating.
When was Sirakoss founded?
Sirakoss was founded in 2011. It employs 1 to 10 people.
Where is Sirakoss based?
Sirakoss is headquartered in Edinburgh, United Kingdom, in the Europe region.
How does Sirakoss make money?
One revenue line is on record: medical Device Sales - Bone Graft Products.
Who are Sirakoss's main competitors?
Direct peers on record are NuVasive (now part of Globus Medical), SeaSpine (now Orthofix Medical), Cerapedics, Xtant Medical and Bone Biologics. Broad incumbents are Medtronic (Sofamor Danek), Stryker, Baxter International and Bioventus. Bonesupport is listed as an emerging player.
Does Sirakoss have an API?
No public API is recorded for Sirakoss.
What industry is Sirakoss in?
Sirakoss's product category is Orthobiologics / Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3841.